CSL Behring is committed to saving lives and improving the quality of life for patients with rare and serious diseases worldwide. This commitment to patient care is reflected in our support of patient programs and activities. CSL Behring funds medical research internally and externally to advance the standard of care for patients with rare diseases. We work with legislators and regulators to help ensure that patients can get access to safe, high-quality plasma-derived and recombinant products that are affordable and/or appropriately reimbursed.
Some of our patient-focused activities are highlighted in "Policy Impact," CSL Behring's public policy newsletter. In addition, several of our key patient programs are listed below:
The Patient Assistance Program provides medically necessary therapies to qualified patients who are uninsured, underinsured, or who cannot afford their prescribed therapy.
The CSL Behring Assurance Program can help people who depend on CSL Behring recombinant and plasma-derived therapies to continue to receive these vital treatments even if they experience a lapse in their third-party, private health insurance.
The Reimbursement Resource Center can help with questions and concerns about insurance, including insurance reimbursement information for CSL Behring products, and help in selecting the coverage that's right for you.
Through the Local Empowerment for Advocacy Development (LEAD) Program, CSL Behring partners with local organizations to effect changes to public policies that impact the users of plasma-derived and recombinant therapies.
Last Updated:
5/19/2010 11:15 AM